Opposing Actions of Endocannabinoids on Cholangiocarcinoma Growth                     (full – 2007)


The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway                                                            (full – 2008)


Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects      (abst – 2008)                       


Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.                                                                          (full – 2010)


Recent advances in the regulation of cholangiocarcinoma growth                     (full – 2010)


The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti- invasion activity at low concentration and apoptosis induction at high concentration. (abst – 2010)                                


Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor.                                                      (abst – 2011) 


The novel cannabinoid receptor GPR55, inhibits cholangiocarcinoma growth (abst – 2011)

&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=80&sortspec=date&resourcety  pe=HWCIT


Share a link for